Customized Autoinjector

Customized Autoinjector Market Outlook

The global customized autoinjector market is poised for substantial growth, with an estimated market size of approximately USD 8.5 billion in 2025 and a projected compound annual growth rate (CAGR) of around 10.2% over the forecast period from 2025 to 2035. This growth trajectory is primarily attributed to the rising prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis, which demand convenient and efficient drug administration methods. Furthermore, the increasing adoption of biologic drugs and the need for patient-centric solutions in healthcare are driving the demand for customized autoinjectors. The shift towards home healthcare and self-administration of medications is also a significant factor contributing to market expansion, as these devices empower patients to manage their conditions more effectively. Enhanced technological innovations and the growing trend for personalized medicine are further expected to play a pivotal role in shaping the future of the customized autoinjector market.

Growth Factor of the Market

Several key factors are propelling the growth of the customized autoinjector market. One of the foremost drivers is the increasing prevalence of chronic diseases, which necessitate regular medication and often require specialized delivery methods. Autoinjectors provide a simple, user-friendly solution that facilitates self-administration, thus improving medication adherence among patients. Additionally, the advancements in technology have led to the development of smart autoinjectors that offer features such as dosage tracking, reminders, and real-time data sharing with healthcare professionals. This integration of technology not only enhances the patient experience but also allows for better disease management. Furthermore, the rise in awareness regarding the benefits of personalized medicine has led to a growing demand for customized solutions tailored to individual patient needs. The ongoing shift towards home healthcare models is also a significant factor, as it emphasizes the need for devices that can be used safely and effectively outside clinical settings. Lastly, regulatory support and initiatives aimed at encouraging innovation in drug delivery systems are expected to further boost market growth.

Key Highlights of the Market

• The global customized autoinjector market is projected to reach USD 15 billion by 2035, with a CAGR of 10.2% from 2025 to 2035.
• Increase in chronic disease prevalence drives demand for user-friendly self-administration devices.
• Technological advancements in smart autoinjectors enhance patient engagement and adherence.
• Growing emphasis on personalized medicine fuels the need for tailored drug delivery systems.
• Expansion of home healthcare services promotes the adoption of customized autoinjectors.

By Product Type

Disposable Autoinjectors:

Disposable autoinjectors are designed for single-use, providing a convenient option for patients who require medication on an occasional or episodic basis. These devices are particularly advantageous in emergency situations, such as the treatment of anaphylaxis, where rapid and effective drug administration is critical. The ease of use associated with disposable autoinjectors encourages patients to self-administer their medication without the need for extensive training or preparation. Additionally, the risk of infection or contamination is significantly reduced since these devices do not require any cleaning or sterilization after use. As healthcare systems increasingly prioritize patient safety and ease of access, the demand for disposable autoinjectors is expected to rise, driving market growth within this segment.

Reusable Autoinjectors:

Reusable autoinjectors are designed for patients who require long-term medication management, allowing for multiple doses before the device needs to be replaced. This type of autoinjector is particularly suited for patients managing chronic conditions, such as rheumatoid arthritis or multiple sclerosis. Reusable devices often come with features that facilitate tracking and management of medication doses, making them a preferred option for patients who need consistent administration of their medication over time. Furthermore, the environmental benefits of reusable devices, including reduced waste and lower costs over the long term, are becoming increasingly appealing to both patients and healthcare systems. As a result, the reusable autoinjector segment is projected to witness significant growth as more patients and providers recognize its advantages.

Smart Autoinjectors:

Smart autoinjectors represent the forefront of innovation in drug delivery systems, integrating advanced technology to enhance the user experience. These devices often incorporate connectivity features, allowing for data sharing with smartphones or other devices used by healthcare professionals. This capability enables real-time monitoring of medication adherence and can provide alerts for upcoming doses, improving patient compliance. Smart autoinjectors also often feature user-friendly interfaces, ensuring that individuals can easily operate the device even in stressful situations. The increasing emphasis on personalized healthcare solutions and the rising demand for technology-driven medical devices are expected to drive the rapid adoption of smart autoinjectors, making them a key segment of the customized autoinjector market.

Manual Autoinjectors:

Manual autoinjectors require users to exert some degree of control during the drug administration process, making them distinct from fully automated devices. While they may not offer the same level of convenience as disposable or smart autoinjectors, manual autoinjectors still hold relevance, particularly in scenarios where cost considerations are paramount. These devices are often simpler in design and can be more affordable, making them accessible for a broader range of patients. Additionally, manual autoinjectors serve as a reliable option for medications that do not require advanced delivery methods or real-time monitoring. As a result, the manual autoinjector segment continues to maintain a presence in the market, particularly in regions or demographics where price sensitivity is a critical factor.

Customized Autoinjectors:

Customized autoinjectors allow for personalization in terms of design, dosing, and delivery methods, catering specifically to the individual needs of patients. This segment is gaining traction as healthcare providers recognize the importance of tailoring treatment options to enhance the patient experience and improve health outcomes. Customized autoinjectors can be designed to accommodate specific patient preferences, including variations in dosage, needle type, and device aesthetics. Such personalization not only boosts patient satisfaction but also enhances adherence to treatment regimens, as patients are more likely to engage with therapies that meet their unique needs. As the trend towards personalized medicine continues to grow, the demand for customized autoinjectors is expected to expand significantly, making it a noteworthy segment in the market.

By Application

Anaphylaxis:

The application of customized autoinjectors in the treatment of anaphylaxis is critical, given the life-threatening nature of this condition. Autoinjectors designed for anaphylaxis typically deliver epinephrine, which is essential for reversing severe allergic reactions promptly. The immediacy offered by these devices can mean the difference between life and death, making their design and reliability paramount. The rising incidence of allergies worldwide, coupled with a growing awareness of the importance of rapid treatment options, is expected to drive demand for autoinjectors specifically tailored for anaphylaxis. Furthermore, initiatives promoting education around allergy management and the need for readily available epinephrine further support market growth in this application area.

Rheumatoid Arthritis:

Customized autoinjectors play a significant role in the management of rheumatoid arthritis, allowing patients to administer biologic medications effectively. These autoinjectors are designed to offer ease of use, which is especially important for individuals who may experience pain or mobility issues associated with their condition. The ability to self-administer medications at home without the need for professional assistance can contribute to better adherence to treatment regimens, leading to improved health outcomes. As the prevalence of rheumatoid arthritis continues to rise globally, the demand for user-friendly autoinjector solutions tailored for this application is expected to increase, further driving market growth.

Multiple Sclerosis:

The management of multiple sclerosis (MS) often involves the use of immunomodulatory therapies that can be administered via customized autoinjectors. These devices facilitate self-administration, allowing patients to maintain their treatment regimens conveniently at home. The psychological aspect of managing a chronic condition like MS can be challenging, and the ability to self-administer medication can empower patients by giving them greater control over their treatment. Moreover, the increasing availability of new therapies for MS, many of which require regular injections, is expected to drive the growth of autoinjectors designed for this specific application, contributing positively to the overall market outlook.

Diabetes:

In the context of diabetes management, customized autoinjectors offer a convenient solution for insulin delivery, particularly for patients who require multiple injections daily. The use of autoinjectors simplifies the process of self-administration, thus minimizing the fear and discomfort often associated with traditional syringe use. Additionally, tailored features, such as adjustable dosage settings and user-friendly designs, enhance the patient experience and promote adherence to treatment protocols. As the global prevalence of diabetes continues to rise, driven by factors such as obesity and sedentary lifestyles, the demand for customized insulin delivery options via autoinjectors is anticipated to grow substantially, shaping a robust segment within the market.

Others:

The “Others” segment encompasses a range of applications that benefit from customized autoinjectors, including treatment for conditions such as psoriasis, migraine, and various hormonal therapies. This diverse application landscape indicates the versatile nature of autoinjectors, which can be adapted for various therapeutic areas. The flexibility in design and dosage delivery of customized autoinjectors allows for innovations that cater to emerging therapeutic needs, thus driving their adoption across different patient populations. As healthcare continues to evolve towards individualized treatment approaches, the relevance of customized autoinjectors in addressing unique medical requirements across a spectrum of conditions will further solidify their position in the market.

By Distribution Channel

Hospitals:

Hospitals represent a significant distribution channel for customized autoinjectors, as these facilities are often the first point of contact for patients requiring such devices. Healthcare providers in hospitals play a crucial role in prescribing and educating patients about the use of autoinjectors, ensuring that individuals understand the importance of self-administration. Hospitals also tend to stock a variety of autoinjectors to accommodate different patient needs, contributing to a steady demand for these products in this segment. Furthermore, the growing trend of patient-centered care within hospital settings is expected to enhance the adoption of customized autoinjectors as part of comprehensive treatment plans.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for customized autoinjectors, providing patients with convenient access to their required medication and devices. The availability of autoinjectors in retail settings allows for easier procurement, enabling patients to start their treatment regimens without delay. Pharmacists also play an essential role in counseling patients about the proper use of autoinjectors and addressing any concerns they may have. As pharmacy chains continue to expand their offerings and enhance their services, the role of retail pharmacies in facilitating the distribution of customized autoinjectors is likely to strengthen, supporting market growth.

Online Pharmacies:

The rise of e-commerce has transformed the distribution landscape for customized autoinjectors, with online pharmacies becoming an increasingly popular option for patients seeking convenience and discretion. Patients can order autoinjectors from the comfort of their homes, often with the option for home delivery, which is particularly appealing for those managing chronic conditions. Online pharmacies offer a wide range of products, allowing patients to choose from various options that suit their specific needs. The growing acceptance of online shopping, especially in the wake of the COVID-19 pandemic, is expected to drive substantial growth in the online pharmacy segment for customized autoinjectors.

Specialty Clinics:

Specialty clinics often focus on specific medical conditions, such as diabetes or autoimmune disorders, making them instrumental in the distribution of customized autoinjectors tailored for particular therapies. These clinics typically have a deeper understanding of the unique requirements of their patient populations and can provide personalized support and education regarding the use of autoinjectors. The expertise offered in specialty clinics enhances patient confidence in self-administration, leading to improved adherence to treatment protocols. As the number of specialty clinics continues to rise, the demand for customized autoinjectors within these settings is expected to grow significantly.

Others:

The “Others” category within distribution channels includes various outlets, such as medical supply stores and direct-to-consumer sales from manufacturers. This segment is noteworthy as it encompasses alternative avenues for patients to access customized autoinjectors. As the healthcare landscape evolves, the availability of autoinjectors through diverse distribution channels ensures that patients have multiple options for procurement, ultimately improving access and convenience. This diversification of distribution channels is expected to contribute positively to the overall growth of the customized autoinjector market.

By Drug Type

Biologics:

The biologics segment is a critical area within the customized autoinjector market, as many biologic medications require specific delivery mechanisms to ensure efficacy. Biologics, which are often used to treat chronic conditions such as rheumatoid arthritis, multiple sclerosis, and certain cancers, necessitate precise and controlled administration. Customized autoinjectors designed for biologics are engineered to accommodate the unique characteristics of these drugs, including temperature sensitivity and stability requirements. As the market for biologics continues to expand, the demand for tailored autoinjector solutions that ensure safe and effective delivery is expected to rise significantly.

Non-Biologics:

Non-biologic drugs encompass a wide range of medications, including traditional small molecules and various therapeutic agents. The use of customized autoinjectors for non-biologics is growing as healthcare providers seek to streamline drug administration processes and improve patient adherence. These devices can be adapted to deliver a variety of non-biologic medications, making them versatile tools in the healthcare setting. As the pharmaceutical industry continues to innovate and develop new non-biologic treatments, the need for effective delivery systems like customized autoinjectors will likely increase, supporting this segment's growth within the overall market.

By Region

North America is expected to dominate the customized autoinjector market, with a market size projected to exceed USD 4 billion by 2035, primarily driven by a high prevalence of chronic diseases and a strong focus on healthcare innovation. The region benefits from well-established healthcare infrastructure, significant investment in research and development, and a growing awareness of self-administration options among patients. The increasing adoption of biologics and the trend toward personalized medicine further bolster market growth in North America, creating an environment conducive to the expansion of customized autoinjectors. Furthermore, the ongoing emphasis on home healthcare solutions is driving demand for these devices, enhancing their relevance in the North American market.

In Europe, the customized autoinjector market is also witnessing robust growth, with a projected CAGR of 9.5% during the forecast period. Factors such as an aging population, rising healthcare expenditure, and increasing prevalence of chronic diseases are contributing to market expansion in this region. Additionally, European countries are focusing on improving healthcare accessibility and patient-centered care, which aligns with the growing demand for solutions like customized autoinjectors. The presence of key players in the pharmaceutical and medical device industries in Europe further supports innovation and product development, making it a vital region for the growth of the customized autoinjector market.

Opportunities

The customized autoinjector market presents numerous opportunities for growth, particularly as healthcare systems globally shift towards more patient-centered approaches. One significant opportunity lies in the integration of digital health technologies, such as mobile applications and telemedicine, with autoinjector devices. These innovations can enhance the patient experience by providing real-time data on medication adherence, reminders for doses, and direct communication with healthcare providers. As the demand for connected health solutions continues to rise, the incorporation of technology into customized autoinjectors will not only improve patient engagement but also open new avenues for market expansion. Additionally, as healthcare providers increasingly recognize the value of personalized treatment plans, there is a growing willingness to invest in tailored autoinjector solutions, further driving opportunities in this space.

Another promising opportunity lies in emerging markets, where rising disposable incomes and increasing access to healthcare are driving demand for advanced medical devices. As countries in regions such as Asia Pacific and Latin America enhance their healthcare infrastructure, the need for convenient and efficient drug delivery systems will grow. Customized autoinjectors can play a crucial role in addressing the unique healthcare challenges faced by these regions, particularly concerning chronic disease management. By focusing on localized production and distribution strategies tailored to specific markets, companies can capitalize on the growing demand for customized autoinjectors in these developing regions, resulting in significant growth potential.

Threats

Despite the promising growth of the customized autoinjector market, several threats could impede its expansion. One of the primary concerns is the potential for regulatory hurdles, as manufacturers must navigate complex approval processes for new devices and technologies. Stringent regulations may slow down the product development cycle, delaying the introduction of innovative autoinjectors to the market. Furthermore, varying regulations across different countries can create challenges for companies seeking to enter new markets, potentially hindering their growth prospects. Additionally, the presence of established competitors with strong brand recognition could pose a threat to new entrants, making it essential for emerging companies to differentiate their products effectively.

Another significant threat to the customized autoinjector market is the prevalence of counterfeit products and substandard devices. As demand for autoinjectors increases, the risk of counterfeit products entering the market also rises, which can compromise patient safety and undermine trust in legitimate products. Ensuring the authenticity and reliability of autoinjectors is crucial for maintaining the integrity of the market. Moreover, as patients become more informed and discerning about their treatment options, companies must continuously innovate and improve their offerings to remain competitive. Failure to keep pace with advancements in technology and patient preferences could lead to a decline in market share for companies that do not adapt accordingly.

Competitor Outlook

• Amgen Inc.
• AbbVie Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company
• Roche Holding AG
• Merck & Co., Inc.
• Antares Pharma, Inc.
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Johnson & Johnson
• Ferring Pharmaceuticals Inc.
• Owen Mumford Ltd.

The competitive landscape of the customized autoinjector market is characterized by a mix of established pharmaceutical companies and innovative startups. The entry of new players with advanced technologies is intensifying competition and driving innovation within the industry. Major companies like Amgen, AbbVie, and Sanofi are leveraging their extensive R&D capabilities to develop cutting-edge autoinjector solutions that cater to patient needs. These companies often engage in strategic partnerships and collaborations to enhance their product offerings and expand their market reach. Additionally, the emphasis on personalized medicine is prompting established players to invest in customized autoinjector designs that align with the growing trend for individualized treatment approaches.

Moreover, several companies are focusing on technological advancements to gain a competitive edge in the customized autoinjector market. For instance, Antares Pharma specializes in developing smart autoinjectors that offer connectivity features, allowing for real-time monitoring and data sharing. This trend towards enhanced functionality and patient engagement is expected to shape the future of the market. Additionally, companies like Johnson & Johnson and Pfizer are actively pursuing mergers and acquisitions to strengthen their portfolios and capitalize on emerging opportunities. As competition intensifies, organizations will need to prioritize innovation, quality, and customer-centric solutions to maintain a competitive advantage.

Key players such as Eli Lilly and Roche Holding AG are also investing in developing user-friendly autoinjectors that facilitate self-administration and improve patient adherence. Their commitment to addressing patient needs through innovative designs positions them favorably in the market. Furthermore, companies are increasingly focusing on sustainability initiatives, such as developing environmentally friendly autoinjectors, to resonate with the growing consumer preference for responsible products. As the customized autoinjector market continues to evolve, staying attuned to market trends and patient preferences will be critical for companies aiming to thrive in this competitive landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Owen Mumford Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Antares Pharma, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ferring Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Customized Autoinjector Market, By Drug Type
    • 6.1.1 Biologics
    • 6.1.2 Non-Biologics
  • 6.2 Customized Autoinjector Market, By Application
    • 6.2.1 Anaphylaxis
    • 6.2.2 Rheumatoid Arthritis
    • 6.2.3 Multiple Sclerosis
    • 6.2.4 Diabetes
    • 6.2.5 Others
  • 6.3 Customized Autoinjector Market, By Product Type
    • 6.3.1 Disposable Autoinjectors
    • 6.3.2 Reusable Autoinjectors
    • 6.3.3 Smart Autoinjectors
    • 6.3.4 Manual Autoinjectors
    • 6.3.5 Customized Autoinjectors
  • 6.4 Customized Autoinjector Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Customized Autoinjector Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Customized Autoinjector market is categorized based on

By Product Type

• Disposable Autoinjectors
• Reusable Autoinjectors
• Smart Autoinjectors
• Manual Autoinjectors
• Customized Autoinjectors

By Application

• Anaphylaxis
• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Others

By Drug Type

• Biologics
• Non-Biologics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• AbbVie Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company
• Roche Holding AG
• Merck & Co., Inc.
• Antares Pharma, Inc.
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Johnson & Johnson
• Ferring Pharmaceuticals Inc.
• Owen Mumford Ltd.